ArticleHealthcare (Basel, Switzerland)2026
Impact of Chronic Kidney Disease Severity on COVID-19 Outcomes: A Retrospective Cohort Study.
Article in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesChronic kidney disease (CKD) is a recognised risk factor for severe COVID-19, but comparative outcomes between conservatively managed CKD patients and those on maintenance haemodialysis (HD) remain incompletely characterised, particularly in Central Asia. This study evaluated the impact of CKD severity on clinical outcomes, inflammatory profiles, and mortality in hospitalised COVID-19 patients.
methodsThis retrospective cohort study reviewed 891 patients hospitalised with COVID-19 at a tertiary infectious disease centre in Almaty, Kazakhstan, between 2020 and 2021. Patients were stratified into three groups: No CKD (
resultsPatients with CKD exhibited significantly higher inflammatory markers, with peak C-reactive protein reaching 168.3 mg/L in the HD group compared to 44.4 mg/L in the No CKD group. In-hospital mortality was highest in the CKD without HD group (34.8%), followed by CKD on HD (21.7%) and No CKD (13.6%). AKI occurred in 35.7% of conservatively managed CKD patients. In multivariate analysis, CKD without HD independently predicted mortality (OR 3.23; 95% CI 1.38-7.63) and AKI (OR 4.12; 95% CI 1.73-10.03). Conversely, established HD status was not a significant independent predictor of mortality after adjusting for age and comorbidities.
conclusionsCKD severity strongly influences COVID-19 prognosis. Paradoxically, conservatively managed CKD patients carry a higher mortality and AKI risk than patients already on maintenance HD, which may be associated with the absence of scheduled volume and metabolic control, although causal inferences cannot be drawn from this observational data. These findings support the need for aggressive monitoring and early nephrological intervention in non-dialysis CKD patients hospitalised with severe viral respiratory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.